Intensity Therapeutics Inc. (NASDAQ:INTS) Shares Shorted: Short Interest Down 36.0% in September

Intensity Therapeutics Inc. (NASDAQ:INTS) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 31,298 shares, a decrease of 36.0% from the August 31st total of 48,911 shares. Based on an average daily trading volume, of 12,048 shares, the days-to-cover ratio is presently 2.6 days. Currently, 1.0% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on INTS shares. HC Wainwright increased their target price on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. Finally, Citigroup reiterated a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Intensity Therapeutics Price Performance

Shares of INTS opened at $3.37 on Thursday. Intensity Therapeutics has a twelve month low of $3.27 and a twelve month high of $43.50. The company has a market capitalization of $10.99 million, a P/E ratio of -0.94 and a beta of 2.76. The firm has a 50 day moving average of $4.15 and a 200 day moving average of $4.63. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 0.01.

Intensity Therapeutics (NASDAQ:INTS) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.24). As a group, equities research analysts anticipate that Intensity Therapeutics will post -2.64 earnings per share for the current fiscal year.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors and stimulate the body’s immune system. The company’s approach is based on its proprietary DfuseRx technology, which is intended to improve the delivery of anticancer agents into tumor cells while promoting an immune response against treated and potentially untreated tumors.

Its lead product candidate, INT230-6, is an investigational intratumoral therapy that combines the cancer-killing agents cisplatin and vinblastine with a formulation designed to facilitate their distribution within tumors.